Articles by Jennifer Woyach, MD
Liso-cel was approved in March 2024 by the FDA for patients with relapsed or refractory CLL.
Dr. Woyach joined Chadi Nabhan, MD, MBA, FACP, to discuss the novel BTK inhibitors pirtobrutinib and LP168.
Jennifer Woyach, MD and colleagues presented the study's results during the 2023 ASCO Annual Meeting.
The phase III study will evaluate pirtobrutinib versus ibrutinib in patients with CLL or SLL.
The study is currently enrolling patients who have previously received a Bruton tyrosine kinase inhibitor.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.